Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Herantis Awaits CDNF Results This Year In Parkinson's Disease

Hopes To Improve Investor Profile With Dual Stock Market Listing

Executive Summary

Executive Interview: Reducing “ER stress” is one of the potential mechanisms of action of a novel candidate Parkinson’s agent being evaluated by Finland’s Herantis, which completed an additional stock market listing, in Sweden, last month.


You may also be interested in...



Tech Transfer Roundup: UCSD Sees Many Benefits From Entrepreneurs In Residence Program

Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.

Herantis CEO Outlines Development Plan For Parkinson's Drug

Pekka Simula, CEO of Herantis, a company born from the merger of Hermo Pharma and Laurantis Pharma, talks to Scrip about the group's lead asset in Parkinson's disease.

Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Topics

UsernamePublicRestriction

Register

SC141444

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel